Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics
Hummingbird Bioscience stands to receive up to USD 290 million in upfront and milestone payments, plus royalties, from Percheron Therapeutics
Percheron Therapeutics aims to commence phase II clinical development of HMBD-002 in CY2026
SINGAPORE, June 26, 2025 (GLOBE NEWSWIRE) -- Hummingbird Bioscience, a biotherapeutics company discovering and developing transformative medicines for hard-to-treat diseases, today announced that it has granted Percheron Therapeutics Limited (ASX: PER) an exclusive worldwide license to develop, manufacture, and commercialize HMBD-002 in all territories and indications. Under the terms of the agreement, Hummingbird Bioscience will be eligible to receive up to USD 290 million in upfront and milestone payments, plus royalties on net sales.
HMBD-002 is a monoclonal antibody therapy targeting VISTA, a novel checkpoint involved in the body's immune response to cancer. HMBD-002 has successfully completed a phase I clinical trial in the United States, under an Investigational New Drug application with the US Food and Drug Administration, which showed the drug to be pharmacologically active and generally safe and well-tolerated. Percheron Therapeutics aims to continue clinical development of HMBD-002 in CY2026.
'Given the potential benefits of VISTA blockade in multiple cancers that have strong evidence of VISTA-mediated immune suppression, HMBD-002 is a scientifically compelling asset for both monotherapy and combination approaches. We are pleased to have Percheron Therapeutics continue the clinical development of HMBD-002,' said Piers Ingram, PhD, co-founder and Chief Executive Officer of Hummingbird Bioscience. 'We have confidence in the potential clinical benefit of HMBD-002 and in Percheron's ability to successfully progress HMBD-002 through the clinic.'
'Hummingbird Bioscience lies at the cutting edge of novel drug design, and we are delighted to partner with them to take forward this very promising drug candidate,' said Dr. James Garner, Chief Executive Officer of Percheron Therapeutics. 'We selected HMBD-002 out of more than a hundred individual drug candidates from more than seventy companies, and we very much hope that this exciting program can bring meaningful benefit to patients confronting the enormous challenge of a cancer diagnosis.'
About HMBD-002 HMBD-002 is a novel anti-VISTA neutralizing antibody, and the only IgG4 isotype anti-VISTA antibody currently in development. HMBD-002 was engineered to bind to VISTA at a specific site that is predicted to be essential for ligand binding and function, thus inhibiting VISTA and neutralizing its immunosuppressive activity without depleting VISTA-expressing cells that play many important roles in the immune system.
About Hummingbird Bioscience
Hummingbird Bioscience is a biotherapeutics company working at the interface of artificial intelligence and human innovation to discover and develop transformative medicines for hard-to-treat diseases. Hummingbird Bioscience's computational and systems biology technologies have generated a pipeline of innovative clinical-stage monoclonal antibodies and antibody-drug conjugates in oncology and autoimmunity. At Hummingbird Bioscience, the commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic. For more information, please visit www.hummingbirdbioscience.com, and follow Hummingbird Bioscience on LinkedIn, X (formerly Twitter), and YouTube.
About Percheron Therapeutics Limited
Percheron Therapeutics Limited [ASX: PER | US OTC: PERCF] is a publicly listed biotechnology company focused on the development and commercialization of novel therapies for oncology and rare diseases. The company's lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA. HMBD-002 has completed a phase I clinical trial in patients with advanced cancer, which has shown the drug to be generally safe and well-tolerated. For more information, please contact info@PercheronTx.com.
CONTACT: Hummingbird Bioscience Media Contact: Crystal Ho c.ho@hummingbirdbio.com media@hummingbirdbio.com +65 6979 5580 Hummingbird Bioscience Investor Contact: investors@hummingbirdbio.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Your Weekly Work Horoscope for The Week of August 18, 2025
Your Weekly Work Horoscope for The Week of August 18, 2025. Discover your Weekly Work Horoscope for each zodiac sign here. Aries When someone asks if anyone has any ideas, you are the first person to open your mouth. You are taking a lot of initiative at the beginning of the week. And your boss is taking notice. Tuesday and Wednesday, all of your mental energy is focused on succeeding at work. Just be careful that you don't use anyone unnecessarily. You don't have to rule the world; you just have to achieve the goals you set out to achieve. And on Thursday and Friday, you'll be achieving them. This weekend, take a break. Be a creature of habit. Be as unambitious as possible. Taurus A financial opportunity will present itself to you on Monday, but it won't be worth the risk. You have enough going on right now to be distracted by wild schemes. On Tuesday and Wednesday, several already underway plans are going to achieve momentum, and you want to be on your toes. Best to keep your options open and stay agile so you can respond to anything. A minor setback (a power struggle) figures on Thursday or Friday, but don't let it rile you. It's just a weird clash of energy. Share your recent work frustrations with a friend or two over the weekend. You'll feel better. Gemini Your righthand person is at your side on Monday. The two of you are ready to take the professional world by storm. Your success these days has everything to do with the strength of the relationships you've built. Midweek, you may start to feel insecure about the direction you're heading in, but that's only because, with so many other people in the picture, there are a ton of unknown variables. Try to nail down some of those variables. And, at the end of the week, try looking at everything from someone else's perspective. You'll be amazed by what you discover. Cancer You're exhausted on Monday. All you want to do is crawl under your desk and take a three-month-long nap. Actually, a nap isn't a half bad idea. Sneak out of the office and do something relaxing or restorative for yourself. Tuesday and Wednesday are full of challenges at work, and, again, your energy level is not going to be as high as you wish it would be, but on Thursday you'll find ways to connect with coworkers and get pumped up about what you're working on these days. On Friday, flexibility is essential. You'll go into the weekend with more vim and vigor than you've had all week. Leo Maybe you can convince someone to send you on a business trip. You have a yen to travel on Monday, and if you could channel your personal desires into your work, you'd be smoking. Your personal life is at an all-time high too. At work, especially Tuesday and Wednesday, coworkers will notice an increase in your confidence and your capacity for leadership. It's all related. There's a chance that someone will misinterpret your boldness as arrogance at the end of the week, but don't cling too tightly to your notions of what other people think. Spend the weekend in listening mode. Prepare yourself to take on each month with your personalized Monthly Horoscope! Virgo Sometimes you just have to take a risk. On Monday, it's risk-taking season. Rather than projecting possible outcomes into the future, focus instead on your own composure. You have no idea what may come your way, and you'll be so much better off if you're poised and prepared for any eventuality. This posture will already start to pay off on Wednesday (someone will mention how fun it is to work with you) and by Thursday you're going to have opened yourself up entirely. You'll learn a ton. An eye-opening conversation on Friday will give way to an expansive weekend. Libra Communicate what's going on and you'll be in the clear. No matter how much control you'd like to have over this project, it's always a better idea to keep your superiors informed. That way, if you decide to call in sick on Tuesday or Wednesday (which you might) someone else at the office will have a clue about what's up. On Thursday, some new inspiration will strike you and you'll charge into work with some fairly significant refinements to the general strategy, but, in general, this week is about being in close touch with your colleagues and turning your camaraderie into something of value. Scorpio Feeling caught up in the moment, you may impulsively sign off on something on Monday. Sometimes being impulsive is smart, because impulsiveness depends upon intuition, and your intuition is pretty good this week. And anyway, with a little willpower and determination you can make anything work. A disagreement among coworkers midweek will give you the opportunity to show off your fairly developed skills at diplomacy. If only you could apply those same skills at home on Friday, when family life will completely consume you. This weekend, you'll get to hone a couple more of your hidden talents. Sagittarius The week begins with an adventure of sorts. A trip out into the field. Maybe a lunch. Joviality and good will figure strongly. Spending time developing your work friendships is as valuable as anything else you could be doing. On Tuesday and Wednesday, you will find a professional outlet for your creativity (your powers of expression are unsurpassed these days). Keeping up the lines of communication (even with a casual email here or there) is essential on Thursday. And on Friday, keep an open mind. All weekend you'll be thinking about ways to expand your horizons. Capricorn It's time for you to impose some structure on all these freewheeling projects. As things stand, nothing seems possible because no one has any idea where to begin. Once you put everything in order, productivity will improve. Everyone's working well together in the middle of the week thanks in no small part to your efforts, and your natural skills as a leader are going to impress someone higher up. Toward the end of the week, keep your eyes on the future rather on immediate priorities. Leave the immediacy to someone else. This weekend, ponder the big picture. Aquarius So many doors are opening for you on Monday. You thought you'd have to do a lot more convincing to get what you want. Instead, you have carte blanche, which means you're going to have to be disciplined about how you proceed. Don't shoot blanks into the dark. Spend the middle of the week being as precise and logical as possible. You'll be amazed by how much you get done. Keep your head down and don't expect any rewards until Thursday afternoon or Friday, when praise and happiness and bonus cash will likely fall upon you. A warning: don't rush out and spend that cash right away. Pisces Hopefully you're rested and alert on Monday. Work is going to require your full attention. A disagreement with the boss is going to set you on edge and finally give definition to the tension you've been sensing for a while. The truth is luck will be on your side. But all week long think before speaking and if you need assistance from someone, by all means, ask for it. (Later in the week, when things have calmed down, you can in turn be of assistance to them.) Friday afternoon you're daydreaming about the future, and the weekend is rich with soul-searching and self-discovery. Discover why 2022 is the year you've been waiting for with your 2022 Premium Horoscope Solve the daily Crossword
Yahoo
4 hours ago
- Yahoo
Green Hydrogen Production Group Closes on Major Investment
A California-based hydrogen production group said it has completed a funding round in support of the company's first 100-kilotonne carbon dioxide removal (CDR) commercial facility. Equatic, which is considered a pioneering company in combined carbon dioxide removal and green hydrogen production, on August 11 announced the successful closure of its Series A round, with Catalytic Capital for Climate and Health (C3H) leading an $11.6-million investment. C3H is a catalytic vehicle by Temasek Trust, along with Kibo Invest, a Singapore-based private investment office with a focus on climate technology. The funding round, with participation from a consortium of global investors, will accelerate the engineering scale-up and commercialization of Equatic's patented seawater electrolysis technology. This substantial capital infusion will support the ongoing engineering of Equatic's CDR commercial facility, alongside further commercialization, manufacturing, and technological development. Equatic's proprietary technology is designed to capture atmospheric carbon dioxide and produce green hydrogen in a single, scalable process, advancing two critical net-zero pathways. 'This investment marks a pivotal moment for Equatic, enabling us to significantly scale our production capabilities and accelerate our mission to deliver durable carbon removal at scale,' said Gaurav N. Sant, founder and chief technology officer for Equatic. 'The Temasek Trust ecosystem has been a foundational partner to Equatic, from early-stage philanthropic backing from Temasek Foundation to catalytic investment through C3H. We welcome Kibo Invest as co-lead and recognize their commitment to invest in companies that are revolutionizing industries and addressing urgent climate challenges.' 'Truly innovative carbon management technologies are needed to mitigate climate change before the consequences become irreversible,' said Lord John Browne, chairman of Equatic's advisory board. Browne also is founder and chairman at BeyondNetZero, and the former CEO of British Petroleum. 'By removing carbon dioxide and simultaneously generating green hydrogen, Equatic's solution provides unique advantages in terms of cost and scalability.' Ryan Tan, head of C3H, said, 'Equatic's technology and approach exemplify the type of bold and scalable innovation that aligns with C3H's mandate. We are delighted to support Equatic's goal in advancing promising climate mitigation solutions that offer permanent, durable carbon removal with green hydrogen production for scalable, tangible impact and commercial benefit.' 'Equatic represents an exciting opportunity to scale deep-tech innovation that addresses two critical needs: decarbonisation and clean energy. As an investor focused on climate solutions, we are proud to partner with C3H and Equatic to help bring this breakthrough technology to commercial scale,' said James Marshall, CEO of Kibo Invest. Equatic's Technology Since commencing operations in 2023, the Equatic technology has been successfully deployed at two pilot plants in Los Angeles and Singapore. The company is now expanding its operations with a demonstration plant in Singapore, known as Equatic-1, and a commercial-scale plant in Canada. In May 2024, Equatic was recognized as a CDR Purchase Prize semifinalist by the U.S. Department of Energy, acknowledging its high-quality, permanent carbon credits and rigorous Monitoring, Reporting, and Verification (MRV) practices. In September 2024, Equatic announced a significant climate breakthrough with the U.S. manufacture of oxygen-selective anodes, which unlock scalable hydrogen production through direct seawater electrolysis. That same month, Equatic was named a finalist for The Earthshot Prize, a prestigious international recognition for groundbreaking solutions to repair the planet. Equatic's commitment to high-integrity carbon removal is underscored by its adoption of an ISO-14064 standard for MRV, first published by Equatic in May 2023. Subsequently, this standard was validated by two leading carbon removal registries, Isometric and making Equatic one of the only marine companies capable of issuing high-quality CDR credits under either registry, with full transparency and auditability. Buyers of Equatic's CDR credits include Boeing, a leading global aerospace company and other large industrial companies committed to market-based mechanisms for decarbonization. —POWER edited this content, which was contained in a press release from Equatic. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
Enigmatig Celebrates NYSE American Listing with Bell Ringing Ceremony, Signaling Next Phase of Global Growth
NEW YORK, Aug. 18, 2025 /PRNewswire/ -- Enigmatig Limited (NYSE American: EGG) ("Enigmatig" or the "Company"), a global business enabler empowering small and medium-sized enterprises (SMEs) to scale across borders, today rang the Closing Bell at the New York Stock Exchange ("NYSE") to mark its recent listing and reaffirm its mission to power the global ambitions of bold, forward-thinking businesses. Enigmatig began trading on June 18, 2025, following the completion of its initial public offering of 3,005,200 Class A ordinary shares at US$5.00 per share including the partial exercise of the underwriters' overallotment option. The offering raised gross proceeds of approximately US$15 million. Prime Number Capital LLC acted as the sole book-running manager for the offering. As one of the few Asia-Pacific headquartered firms in its sector to list on the NYSE American, this accomplishment underscores Enigmatig's role as a trusted partner for SMEs navigating high-stakes cross-border expansion, regulatory complexities, and new market entries. Desmond Foo, Founder and CEO of Enigmatig, said, "Today's bell ringing is a proud milestone in our 15-year journey of enabling SMEs to achieve their international ambitions. Our listing strengthens our foundation for bold, global expansion, enabling us to deepen our service capabilities, advance our RegTech innovations, and extend our reach across the world's key financial hubs. Enigmatig was built to guide clients throughout their expansion journey – from incorporation to licensing, compliance, and strategic growth – delivering clarity, precision, and partnership every step of the way." Mingwen Teo, the Company's Director and CFO, added, "Our successful IPO and strong first-half performance validate the strength of our business model and the growing demand for comprehensive, technology-enabled licensing and compliance solutions. This ceremony is not just a celebration of our listing, but also a reaffirmation of our long-term vision to empower compliance globally while creating sustainable value for our clients and shareholders." With its IPO proceeds, Enigmatig is driving its next wave of growth by: Expanding its leadership and specialist teams across key markets and verticals Accelerating RegTech and automation innovation to streamline compliance Enhancing strategic advisory with sharper, data-driven insights Pursuing targeted M&A to strengthen its global service offerings Growing its presence in high-potential markets to serve clients closer to where they operate and aspire to operate Founded in 2010, Enigmatig has built a strong track record across global financial hubs and offshore jurisdictions, including Singapore, Hong Kong, Shanghai, London, Cyprus, and Belize, delivering tailored solutions across the full business lifecycle, from company incorporation to ongoing compliance and strategic advisory. Its proprietary CRM platform, integrating KYC, AML, and transaction monitoring tools, positions RegTech at the core of the Company's growth strategy, allowing smarter, faster compliance for both new and existing clients. For photos, a video replay and other content from the event, please visit: About Enigmatig Limited Enigmatig is an international business enabler dedicated to helping small and medium-sized enterprises (SMEs) achieve their international ambitions. Since 2010, we have connected businesses with the expertise, infrastructure, and regulatory support needed to succeed in cross-border markets. With deep capabilities in FX brokerage consultancy, licensing, RegTech, FinTech, and corporate services, Enigmatig delivers tailored solutions across the full business lifecycle – from company incorporation to ongoing compliance. Our experienced team specializes in navigating complex regulatory environments across global financial hubs and key offshore centers, including London, Cyprus, and Belize. Headquartered in Singapore with a strategic presence in Hong Kong, Shanghai, London, and a representative desk in Bangkok, Enigmatig supports a diverse and growing international client base. For more information, please visit: Safe Harbor Statement Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "may," "could," "will," "should," "would," "expect," "plan," "aim," "intend," "anticipate," "believe," "estimate," "predict," "is/are likely to," "potential," "project" or "continue" or the negative of these terms or other comparable or similar terminology. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the SEC, which are available for review at Media & Investor Contacts: investors@ View original content to download multimedia: SOURCE Enigmatig
